Decursinol angelate blocks transmigration and inflammatory activation of cancer cells through inhibition of PI3K, ERK and NF-κB activation

Cancer Letters

Volumn 296, Issue 1, 2010, Pages 35-42

  Kim, Won Jung ^a   Lee, Min Young ^a   Kim, Jung Hee ^a   Suk, Kyoungho ^b   Lee, Won Ha ^a  

^a Kyungpook National University   (South Korea)

^b Kyungpook National University School of Medicine   (South Korea)

Author keywords

Adhesion; Cancer; Decursinol angelate; Inflammation; Transmigration

Indexed keywords

BETA1 INTEGRIN; CELL ADHESION MOLECULE; COUMARIN DERIVATIVE; CYTOKINE; DECURSINOL ANGELATE; GELATINASE B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; CANCER CELL; CANCER INHIBITION; CANCER INVASION; CELL ADHESION; CELL MIGRATION; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVITY; ENZYME INHIBITION; EXTRACELLULAR MATRIX; HUMAN; HUMAN CELL; MIGRATION INHIBITION; PRIORITY JOURNAL;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANGELICA; ANTI-INFLAMMATORY AGENTS; ANTINEOPLASTIC AGENTS; BENZOPYRANS; BREAST NEOPLASMS; BUTYRIC ACIDS; CELL ADHESION; CELL LINE, TUMOR; CELL MOVEMENT; DNA PRIMERS; ENZYME ACTIVATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; FIBROSARCOMA; FLOW CYTOMETRY; GELATIN; HUMANS; INFLAMMATION; MATRIX METALLOPROTEINASE 9; NEOPLASM INVASIVENESS; NF-KAPPA B; PROTEIN KINASE C; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

ANGELICA GIGAS;

EID: 77954757786     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2010.03.012     Document Type: Article

References (32)

1. Lee S., Lee Y.S., Jung S.H., Shin K.H., Kim B.-K., Kang S.S. Anti-tumor activities of decursinol angelate and decursin from Angelica gigas. Arch. Pharm. Res. 2003, 26:727-730.
2. Lee H.J., Lee H.J., Lee E.O., Lee J.H., Lee K.S., Kim K.H., et al. In vivo anti-cancer activity of Korean Angelica gigas and its major pyranocoumarin decursin. Am. J. Chinese Med. 2009, 37:127-142.
3. Yim D., Singh R.P., Agarwal C., Lee S., Chi H., Agarwal R. A novel anticancer agent, decursin, induces G1 arrest and apoptosis in human prostate carcinoma cells. Cancer Res. 2005, 65:1035-1044.
4. Jiang C., Guo J., Wang Z., Xiao B., Lee H.J., Lee E.O., et al. Decursin and decursinol angelate inhibit estrogen-stimulated and estrogen-independent growth and survival of breast cancer cells. Breast Cancer Res. 2007, 9:R77.
5. Jiang C., Lee H.J., Li G.X., Guo J., Malewicz B., Zhao Y., et al. Potent antiandrogen and androgen receptor activities of an Angelica gigas-containing herbal formulation: identification of decursin as a novel and active compound with implications for prevention and treatment of prostate cancer. Cancer Res. 2006, 66:453-463.
6. Song G.Y., Lee J.H., Cho M., Park B.S., Kim D.E., Oh S. Decursin suppresses human androgen-independent PC3 prostate cancer cell proliferation by promoting the degradation of beta-catenin. Mol. Pharmacol. 2007, 72:1599-1606.
7. Kim J.H., Kim J.H., Lee Y.M., Ahn E.M., Kim K.W., Yu Y.S. Decursin inhibits VEGF-mediated inner blood-retinal barrier breakdown by suppression of VEGFR-2 activation. J. Cerebr. Blood Flow Metab. 2009.
8. Son S.H., Kim M.J., Chung W.Y., Son J.A., Kim Y.S., Kim Y.C., et al. Decursin and decursinol inhibit VEGF-induced angiogenesis by blocking the activation of extracellular signal-regulated kinase and c-Jun N-terminal kinase. Cancer Lett. 2009, 280:86-92.
9. Jung M.H., Lee S.H., Ahn E.M., Lee Y.M. Decursin and decursinol angelate inhibit VEGF-induced angiogenesis via suppression of the VEGFR-2-signaling pathway. Carcinogenesis 2009, 30:655-661.
10. Kim J.H., Jeong J.H., Jeon S.T., Kim H., Ock J., Suk K., et al. Decursin inhibits induction of inflammatory mediators by blocking nuclear factor-kappaB activation in macrophages. Mol. Pharmacol. 2006, 69:1783-1790.
11. Yang E.J., Song G.Y., Lee J.S., Yun C.Y., Kim I.S. A novel (S)-(+)-decursin derivative, (S)-(+)-3-(3,4-dihydroxy-phenyl)-acrylic acid 2,2-dimethyl-8-oxo-3,4-dihydro-2H,8H-pyrano[3,2-g]chromen-3-yl-ester, inhibits ovalbumin-induced lung inflammation in a mouse model of asthma. Biol. Pharm. Bull. 2009, 32:444-449.
12. Mantovani A., Allavena P., Sica A., Balkwill F. Cancer-related inflammation. Nature 2008, 454:436-444.
13. Philip M., Rowley D.A., Schreiber H. Inflammation as a tumor promoter in cancer induction. Semin. Cancer Biol. 2004, 14:433-439.
14. Lee W.H., Kim S.H., Lee Y., Lee B.B., Kwon B., Song H., et al. Tumor necrosis factor receptor superfamily 14 is involved in atherogenesis by inducing proinflammatory cytokines and matrix metalloproteinases. Arterioscl. Throm. Vas. Biol. 2001, 21:2004-2010.
15. Kim W.J., Lee W.H. LIGHT is expressed in foam cells and involved in destabilization of atherosclerotic plaques through induction of matrix metalloproteinase-9 and IL-8. Immune Network 2004, 4:116-122.
16. Bae E., Kim W.J., Kang Y.M., Suk K., Koh E.M., Cha H.S., et al. Glucocorticoid-induced tumour necrosis factor receptor-related protein-mediated macrophage stimulation may induce cellular adhesion and cytokine expression in rheumatoid arthritis. Clin. Exp. Immunol. 2007, 148:410-418.
17. Kim W.J., Bae E.M., Kang Y.J., Bae H.U., Hong S.H., Lee J., et al. Immunology 2006, 119:421-429.
18. Meng X.N., Jin Y., Yu Y., Bai J., Liu G.Y., Zhu J., et al. Characterisation of fibronectin-mediated FAK signalling pathways in lung cancer cell migration and invasion. Br. J. Cancer 2009, 101:327-334.
19. Teranishi F., Takahashi N., Gao N., Akamo Y., Takeyama H., Manabe T., et al. Phosphoinositide 3-kinase inhibitor (wortmannin) inhibits pancreatic cancer cell motility and migration induced by hyaluronan in vitro and peritoneal metastasis in vivo. Cancer Sci. 2009, 100:770-777.
20. May R.C., Machesky L.M. Phagocytosis and the actin cytoskeleton. J. Cell. Sci. 2001, 114:1061-1077.
21. Kim D., Kim S., Koh H., Yoon S.O., Chung A.S., Cho K.S., et al. Akt/PKB promotes cancer cell invasion via increased motility and metalloproteinase production. Faseb J. 2001, 15:1953-1962.
22. Yoon S.O., Shin S., Lee H.J., Chun H.K., Chung A.S. Isoginkgetin inhibits tumor cell invasion by regulating phosphatidylinositol 3-kinase/Akt-dependent matrix metalloproteinase-9 expression. Mol. Cancer Ther. 2006, 5:2666-2675.
23. Maeda-Yamamoto M., Suzuki N., Sawai Y., Miyase T., Sano M., Hashimoto-Ohta A., et al. Association of suppression of extracellular signal-regulated kinase phosphorylation by epigallocatechin gallate with the reduction of matrix metalloproteinase activities in human fibrosarcoma HT1080 cells. J. Agric. Food Chem. 2003, 51:1858-1863.
24. Takino T., Miyamori H., Watanabe Y., Yoshioka K., Seiki M., Sato H. Membrane type 1 matrix metalloproteinase regulates collagen-dependent mitogen-activated protein/extracellular signal-related kinase activation and cell migration. Cancer Res. 2004, 64:1044-1049.
25. Kim A., Kim M.J., Yang Y., Kim J.W., Yeom Y.I., Lim J.S. Suppression of NF-kappaB activity by NDRG2 expression attenuates the invasive potential of highly malignant tumor cells. Carcinogenesis 2009, 30:927-936.
26. Lee H.Y., Park K.S., Kim M.K., Lee T., Ryu S.H., Woo K.J., et al. A small compound that inhibits tumor necrosis factor-alpha-induced matrix metalloproteinase-9 upregulation. Biochem. Biophys. Res. Commun. 2005, 336:716-722.
27. Park H.J., Chung H.J., Min H.Y., Park E.J., Hong J.Y., Kim W.B., et al. on the invasion of human fibrosarcoma cells by down-regulating the matrix metalloproteinases. Biochem. Pharmacol. 2005, 71:21-31.
28. Brooks S.A., Lomax-Browne H.J., Carter T.M., Kinch C.E., Hall D.M. Molecular interactions in cancer cell metastasis. Acta Histochem. 2009.
29. Sica A., Allavena P., Mantovani A. Cancer related inflammation: the macrophage connection. Cancer Lett. 2008, 267:204-215.
30. Mantovani A., Schioppa T., Porta C., Allavena P., Sica A. Role of tumor-associated macrophages in tumor progression and invasion. Cancer Metast. Rev. 2006, 25:315-322.
31. Clevers H. At the crossroads of inflammation and cancer. Cell 2004, 118:671-674.
32. Lu H., Ouyang W., Huang C. Inflammation, a key event in cancer development. Mol. Cancer Res. 2006, 4:221-233.